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Epidermal growth factor (EGF) has been reported to
either sensitize or protect cells against ionizing radia-
tion. We report here that EGF increases radiosensitivity
in both human fibroblasts and lymphoblasts and down-
regulates both ATM (mutated in ataxia-telangiectasia
(A-T)) and the catalytic subunit of DNA-dependent pro-
tein kinase (DNA-PKcs). No further radiosensitization
was observed in A-T cells after pretreatment with EGF.
The down-regulation of ATM occurs at the transcrip-
tional level. Concomitant with the down-regulation of
ATM, the DNA binding activity of the transcription fac-
tor Sp1 decreased. A causal relationship was established
between these observations by demonstrating that up-
regulation of Sp1 DNA binding activity by granulocyte/
macrophage colony-stimulating factor rapidly reversed
the EGF-induced decrease in ATM protein and restored
radiosensitivity to normal levels. Failure to radiosensi-
tize EGF-treated cells to the same extent as observed for
A-T cells can be explained by induction of ATM protein
and kinase activity with time post-irradiation. Although
ionizing radiation damage to DNA rapidly activates
ATM kinase and cell cycle checkpoints, we have pro-
vided evidence for the first time that alteration in the
amount of ATM protein occurs in response to both EGF
and radiation exposure. Taken together these data sup-
port complex control of ATM function that has impor-
tant repercussions for targeting ATM to improve radio-
therapeutic benefit.
Functional loss of the ATM1 protein, mutated in the human
genetic disorder ataxia-telangiectasia (A-T) (1), leads to a pleio-
tropic phenotype including neurological abnormalities, immu-
nodeficiency, and a predisposition to develop a number of ma-
lignancies, primarily leukemias and lymphomas (2). The
characteristic most widely studied in A-T is hypersensitivity to
ionizing radiation (3–5) that appears to be due to an inability of
ATM to recognize and facilitate the repair of a subcategory of
double strand breaks or a form of damage that is converted into
a double strand break in DNA (6, 7). It is also likely that
recognition of a specific form of DNA damage represents the
trigger for ATM to activate a number of cell cycle checkpoints
(8, 9). A-T cells are defective in the phosphorylation of p53 on
serine 15 and serine 20 and dephosphorylation at serine 376
after exposure of cells to ionizing radiation (10–12). Evidence
for a direct involvement of ATM with p53 was provided by the
demonstration that these two molecules interact directly (13)
and ATM phosphorylates p53 on serine 15 in response to DNA
damage (14, 15). Pre-existing ATM protein is rapidly activated
by ionizing radiation and radiomimetic agents by an unde-
scribed mechanism (13–15). Exposure of cells to ionizing radi-
ation fails to change either the subcellular distribution or the
total amount of cellular ATM protein (16–18). Furthermore,
ATM protein levels are relatively constant throughout the cell
cycle in human fibroblasts (17). These data point to a post-
translational mechanism of activation for ATM. However,
there is evidence for alteration in the amount of ATM under
certain conditions. Although ATM is not detectable by immu-
nohistochemical staining in quiescent myoepithelial cells lin-
ing normal breast ducts, significant expression is observed in
the proliferative myoepithelium of sclerosing adenosis (19). In
addition the amount of ATM protein changes dramatically in
quiescent lymphocytes (PBMCs) in response to mitogenic
agents (20). In the latter study a 6–10-fold increase in ATM in
PBMCs was observed in response to PHA, reaching a maxi-
mum by 3–4 days. As the amount of ATM protein increased, so
too did its protein kinase activity. Clearly this is a slow re-
sponse compared with the rapid activation of ATM post-irradi-
ation. Alteration in the amount of the ATM protein could occur
by transcriptional control at the promoter. The housekeeping
gene NPAT/E14/CAND3 lies ;0.55 kb from the 59 end of the
ATM gene (21–23). These genes share a bidirectional promoter
that contains CCAAT boxes and 4 consensus sites for the Sp1
transcription factor (21, 22). Further delineation of the ATM
promoter is required to assist in understanding the transcrip-
tional regulation of ATM.
ATM is located predominantly in the nucleus of proliferating
cells, which is in keeping with its role in DNA damage recog-
nition and cell cycle control, but ATM has also been detected in
cytoplasmic vesicles (16, 17, 24). Since ATM has been impli-
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cated in more general intracellular signaling and since it re-
sponds to mitogenic agents, we studied its possible regulation
by epidermal growth factor (EGF) that alters cellular response
to radiation. EGF enhances the radiosensitivity of some cell
types (25–28) and increases the radioresistance of other cells
(29). We show here that EGF enhanced the radiosensitivity of
both fibroblasts and lymphoblasts, and this was associated
with a decrease in ATM. Reduction in ATM protein was accom-
panied by a decrease in the amount of Sp1 DNA binding activ-
ity. We also demonstrate that ATM protein is rapidly restored
to constitutive levels by both granulocyte/macrophage colony-
stimulating factor (GM-CSF) and ionizing radiation, and this
appears to be achieved by increasing Sp1 DNA binding activity.
EXPERIMENTAL PROCEDURES
Materials—Normal human skin fibroblasts HSF7 and NFF were
from healthy donors expressing ATM protein; A-T fibroblasts GM03395
were obtained from Coriell Cell Repositories. Lymphoblastoid cells were
established by Epstein-Barr virus transformation from healthy individ-
uals, C3ABR, C28ABR, C35ABR, C2ABR, and C31ABR. All cells were
grown at 37 °C in a humidified atmosphere of 5% CO2 and 95% air in
RPMI 1640 medium supplemented with 10% fetal calf serum. Irradia-
tion of cells was performed at room temperature using a 137Cs source
delivering gamma rays at a dose rate of 2.8 Gy/min. EGF (R & D
Systems) was added at a concentration of 50 ng/ml to the culture
medium of log-phase cultures or serum-reduced fibroblasts for various
times as indicated. The antibodies used are as follows: p53 monoclonal
antibody (polyclonal antibody 1801) and polyclonal Sp1 antibody
(Sp1pEp2) were from Santa Cruz Biotechnology; monoclonal a-actin
(A4700) was from Sigma; polyclonal anti-Ku and DNA-PKcs antibodies
were obtained from Susan Lees-Miller, University of Calgary, Canada;
anti-phosphorylated p53 serine 15 was obtained from New England
Biolabs; and monoclonal ATM (CT1) and polyclonal ATM raised in
sheep (ATM5BA) antibodies were generated in this laboratory.
Cell Survival—Logarithmically growing lymphoblastoid cells were
incubated with or without EGF (50 ng/ml) for 16 h prior to exposure to
ionizing radiation (2.5 Gy/min, 137Cs). Cell viability was determined at
daily intervals between 1 and 4 days by adding 0.1 ml of 0.4% trypan
blue to a 0.5-ml cell suspension as described previously, and viable cells
were counted (30).
Immunoblotting—EGF treatment was carried out on log-phase cells
for different times as indicated. After washing in PBS, 5 3 106 cells
were resuspended in 40 ml of nuclear extraction buffer (25 mM Hepes,
pH 8, 0.25 M sucrose, 1 mM EGTA, 5 mM MgSO4, 50 mM NaF, 1 mM DTT,
1 mM PMSF) and disrupted by at least 4 freeze-thaw cycles. Insoluble
material was removed by centrifugation at 13,000 3 g for 20 min.
Protein concentration was determined using a Bio-Rad DC protein
assay kit according to the manufacturer’s recommendations, and 50–
100 mg was used per sample. Protein samples were separated on 5 or
10% denaturing gels and blotted on nitrocellulose membranes. After
blocking in 4% milk powder, 0.1% Tween 20, PBS for at least 1 h, the
blot was incubated for 1 h at room temperature or overnight at 4 °C,
with the relevant primary antibody. The blot was washed three times in
0.1% Tween 20/PBS and incubated with secondary peroxidase-conju-
gated antibody for 1 h. Following several washing steps, the blot was
developed using a chemiluminescence kit (DuPont).
mRNA Determination—Changes in ATM mRNA in lymphoblastoid
cells were determined by quantitative PCR as described (31). In short,
known amounts of a 402-bp DNA fragment corresponding to an ATM
mutation lacking exon 38 (5319 G to A) was used as a competitor during
amplification of the corresponding region in ATM cDNA from normal
cells, which gives a 544-bp fragment (nucleotides 5122–5665). A series
of 2-fold dilutions were employed to find the equivalence point and thus
a measure of the amount of ATM mRNA. Expression of mRNA was also
determined by Northern blotting. Briefly, total RNA was isolated from
log-phase cells with an RNA isolation kit (Qiaquick, Qiagen) according
to the manufacturer’s instructions, and 20 mg of RNA/lane was sepa-
rated on a 1% agarose gel. Blotting of RNA on nylon membrane (Hy-
bond-N, Amersham Pharmacia Biotech) was performed overnight by
capillary force followed by hybridization with an ATM cDNA probe.
Gel Retardation Assay (Electrophoretic Mobility Shift Assay)—The
DNA binding activity of transcription factor Sp1 was determined by
modification of a method described previously (32). Briefly, 107 cells
were washed in ice-cold PBS, resuspended in 400 ml of buffer A (10 mM
Hepes, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.2
mM PMSF), and incubated for 15 min on ice. After addition of 25 ml of
10% Nonidet P-40, the cells were subsequently vortexed for 10 s and the
nuclei pelleted by centrifugation (1 min, 13,000 3 g at 4 °C). The
nuclear pellet was resuspended in 40 ml of buffer C (20 mM Hepes, pH
7.9, 400 mM KCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1 mM DTT, 0.2
mM PMSF) and rotated for 30–60 min at 4 °C to elute nuclear proteins.
After additional centrifugation for 15 min at 4 °C the supernatant
containing the nuclear proteins was aliquoted, frozen in liquid nitrogen,
and stored at 270 °C until used in binding reactions. Approximately 35
fmol of 32P-radiolabeled double-strand Sp1 consensus sequence (59-
ATTCGATCGGGGCGGGGCGAGC-39; Promega) (labeled using T4
polynucleotide kinase) was incubated with 10 mg of nuclear extract in
the presence of 1 mg of herring sperm DNA and 20 mg of BSA in binding
buffer (10 mM Hepes, pH 7.9, 50 mM KCl, 0.5 mM EDTA, 10% glycerol,
1% Nonidet P-40, 5 mM DTT, 0.2 mM PMSF) in a 20-ml reaction. Binding
was for 25 min at room temperature before DNA-protein complexes
were separated on a native 5% acrylamide gel. Exposure time to x-ray
film was usually 30–45 min.
Luciferase Assays—The ATM promoter was amplified from human
genomic DNA using primers (forward, 5-TCCCCCGGGGGAGATCAA-
AACCACAGCAGG, and reverse, 5-CCCAAGCTTGGGCGTTCTCTCG-
CCTCCTCCCGTG). The 615-bp amplification product was cloned into
the pGL3-basic luciferase reporter vector (Promega) using a SmaI/
HindIII digest. This construct (pGL3-ATM) was cotransfected with the
pRL-CMV vector (Promega) at a ratio of 2:1 into lymphoblastoid cells by
electroporation (280 V, 960 microfarads, 1 pulse). Thirty six hours after
electroporation the cells were incubated with 50 ng/ml EGF for a fur-
ther 16 h before cell extracts were prepared. Luciferase activity was
measured using the Dual Luciferase Assay (Promega, E1910). Briefly,
100 ml of firefly luciferase substrate (LARII) and 20 ml of cell extract
were mixed, and the reaction was immediately measured for 10 s. Then
100 ml of Renilla luciferase substrate including an inhibitor for firefly
luciferase (Stop & Glow) was added, and light emission was detected for
another 10-s interval. The ratio of both measurements (pGL/pRL) re-
sults in the relative luciferase activity, avoiding variabilities in trans-
fection. The absolute values of luminescence measured (relative light
unit) was generally in the range of 5z104–5z106. The untreated control
was set to 1.
ATM Kinase Assay—ATM kinase activity after EGF treatment was
determined using the method described by Canman et al. (15). For
whole cell lysate isolation, cells were lysed on ice in TGN buffer (50 mM
Tris, pH 7.5, 50 mM b-glycerophosphate, 150 mM NaCl, 10% glycerol, 1%
Tween 20, 1 mM NaF, 1 mM Na3VO4, 1 mM PMSF, 2 mg/ml pepstatin, 5
mg/ml leupeptin, 10 mg/ml aprotinin, 1 mM DTT). After centrifugation at
13,000 3 g for 1 min, 2 mg of extract was precleared with mouse
immunoglobulin G and protein A/G-Sepharose beads. ATM was immu-
noprecipitated with anti-ATM antibody (ATM5BA) and kinase activity
determined as described.
RESULTS
EGF Sensitizes Cells to Radiation—Engagement of the EGF
receptor by EGF and other ligands initiates signal transduction
pathways giving rise to mitogenesis and can also alter the
radiosensitivity status of cells (25–29). We determined whether
EGF might increase the sensitivity of human fibroblasts and
lymphoblasts by incubating cells in EGF for 16 h prior to
exposure to radiation (1–4 Gy). The results in Fig. 1A demon-
strate that EGF-treated lymphoblastoid cells are more sensi-
tive to radiation, and this is observed over the radiation dose
range 1–4 Gy (Fig. 1B). The effect of EGF treatment was
significant for both dose and time course experiments for
C3ABR; p 5 0.0023 (a), p 5 0.0053 (b) for dose and p 5 0.0065
(a) and p 5 0.07 (b) for time course. On the other hand treat-
ment of A-T cells with EGF failed to increase the radiosensi-
tivity of these cells (Fig. 1, A and B). A similar sensitization was
observed in EGF-treated control fibroblasts, but again no fur-
ther increase in sensitivity was revealed in EGF-treated A-T
fibroblasts (Fig. 1C). We observed that EGF receptor was acti-
vated under these conditions (results not shown).
EGF Treatment Reduces ATM Protein Expression—Since ra-
diosensitivity and abnormalities in mitogenesis and other sig-
naling pathways are characteristic of the A-T phenotype, we
initially determined whether the radiosensitizing effect of EGF
might be due to alteration in the amount of ATM protein in
normal control cells. Immunoblotting with anti-ATM antibod-
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ies showed that the amount of ATM protein was reduced sig-
nificantly with time after incubation with EGF in normal fi-
broblasts (Fig. 2A). No ATM was detected in negative control
AT3ABR cells, as expected (16). The same pattern of reduction
was observed for the catalytic subunit of DNA-dependent pro-
tein kinase, DNA-PKcs, after EGF treatment, but Ku, the DNA
damage recognition component of DNA-dependent protein ki-
nase, remained largely unchanged (Fig. 2A). It is evident that
the amount of DNA-PKcs is normal in the A-T cell line,
AT3ABR, when compared with C3ABR. EGF treatment of
C3ABR lymphoblastoid cells revealed a similar pattern of loss
of expression of ATM, down to 30% by 9 h post-treatment (Fig.
2B). A similar pattern of decrease was also observed for DNA-
PKcs (Fig. 1B). To test the universality of these observations
we employed several control lymphoblastoid cell lines. In all
four control lines investigated, ATM protein decreased signifi-
cantly after EGF treatment (Fig. 2C). It is evident from the
positive control (100 mg of extract from the lymphoblastoid cell
line, C3ABR) that the amount of ATM protein in HSF7 fibro-
blasts (at equal loading) is considerably lower than that in
lymphoblastoid cells (Fig. 2A).
Effect of EGF on mRNA Expression—Since EGF caused a
marked decrease in the amount of ATM protein, it was possible
that this was due to transcriptional down-regulation. To mon-
itor changes to ATM mRNA in lymphoblastoid cells, we em-
ployed quantitative reverse transcriptase-PCR as described
FIG. 2. Effect of EGF incubation on the amount of ATM protein
in control cells. A, ATM protein levels in fibroblasts (HSF7) treated
with EGF (50 ng/ml). 200 mg of HSF7 protein was loaded in each lane
and immunoblotted with anti-ATM antibody (ATM-4BA) (16). Positive
(C3ABR lymphoblastoid cell extracts, 100 mg) and negative (AT3ABR
lymphoblastoid cell extracts, 100 mg) controls were also loaded. DNA-
PKcs, the catalytic subunit of DNA-dependent protein kinase, was
determined using the antibody DPKI (kindly provided by Susan Lees-
Miller, University of Calgary). The same cell lines were employed as
controls for DNA-PKcs. Immunoblotting was also carried out for
Ku70/86 using a mouse polyclonal antibody that detects both forms, and
this acted effectively as a loading control. B, effect of EGF (50 ng/ml)
incubation on ATM protein in (C3ABR) lymphoblastoid cells. Immuno-
blotting was carried out with anti-ATM antibody (CT-1) using 40 mg of
extracts in each lane. DNA-PKcs was determined using immunoblot-
ting with DPKI, and actin was used as a loading control. C, EGF
reduces ATM protein in different lymphoblastoid cell lines. The cells
were incubated with EGF (50 ng/ml) for 20 h and ATM levels deter-
mined by immunoblotting in C3ABR, C28ABR, C35ABR, and C31ABR.
Protein loading in each lane was determined by Ponceau S staining (not
shown).
FIG. 1. EGF sensitizes human cells to ionizing radiation. A,
effect of increasing radiation dose on survival of control (C3ABR) and
A-T (AT1ABR) lymphoblastoid cells untreated or pretreated with EGF
(50 ng/ml) for 16 h prior to irradiation. Viability was determined by
trypan blue exclusion at 72 h post-irradiation. (2) and (1) refer to EGF
addition. B, effect of g-radiation (4 Gy) on survival of C3ABR and
AT1ABR cells with time after irradiation. Cells were untreated and
pretreated with EGF as in A above. C, effect of EGF (50 ng/ml) for 16 h
on radiation killing in control (NFF) and A-T (GM 3395) fibroblast cells.
In this case survival was determined by colony formation. In each case
three independent experiments were carried out, and values were fitted
by nonlinear repression and calculated curve parameters (a, b) sub-
jected to Student’s t test.
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previously (31). A DNA fragment (402 bp) corresponding to an
ATM mutation (G5319A), which lacks exon 38, was used as a
competitor for ATM cDNA amplification (nucleotides 5122–
5665, 544 bp in size) in a series of 2-fold dilutions from C3ABR
cells. After 8 h of treatment with EGF, an equivalent point was
reached at 0.625 attomol/ml of competitor compared with 1.25
attomol/ml for untreated cells representing an ;2-fold reduc-
tion in ATM mRNA in response to EGF (Fig. 3A). After 16 h of
treatment with EGF the equivalent point was reached at ;0.4
attomol representing a 3-fold reduction in ATM mRNA. North-
ern blot analysis revealed that ATM mRNA was reduced to
60% after incubation of normal fibroblasts (HSF7) with EGF
for 8 h and reached a plateau at ;30% of the untreated value
at 12–24 h post-treatment, which parallels the changes shown
by reverse transcriptase-PCR in lymphoblastoid cells (Fig. 3B).
Reduced Sp1 Binding Activity after EGF Treatment—A sim-
ilar genomic organization at the ATM locus exists for the hu-
man and mouse genes where ATM and nuclear protein at the
A-T locus (NPAT) are arranged ;0.5 kb apart in a head-to-head
configuration (Fig. 5A) (21, 22). These two genes are tran-
scribed from a central bidirectional promoter that contains
several binding sites for the transcriptional factor, Sp1 (33).
Since ATM mRNA and protein were reduced after EGF treat-
ment, we predicted that this might be due to interference with
or reduced Sp1 DNA binding activity. Use of gel-shift analysis
with an oligonucleotide-binding consensus sequence for Sp1
revealed the presence of a single, well defined, retarded band
(Fig. 4A). The amount of Sp1 binding in extracts from C3ABR
cells decreased with time after EGF treatment (Fig. 4A). A
decrease of ;50% by 12 h post-treatment, leveling off at later
times, paralleled the decrease in the amount of ATM mRNA
and protein seen previously. To establish the specificity of this
binding, we added anti-Sp1 antibody to the incubation mixture
and observed a supershift of the retarded band (Fig. 4A, lower
panel). A control antibody against p53 did not alter migration
of the band. In addition excess cold Sp1 binding consensus
oligonucleotide successfully competed for binding, whereas cold
AP-1 binding oligonucleotide failed to do so (results not shown).
Under these conditions the amount of Sp1 protein did not
change (Fig. 4B). When Sp1 binding was determined in four
additional cell lines a similar decrease was observed in all cases
(Fig. 4C).
Effect of EGF on ATM Promoter—To confirm the effect of
EGF on the transcriptional regulation of ATM, we cloned the
common promoter region between ATM and NPAT into a lucif-
erase reporter construct (Fig. 5) and carried out transient
transfections in control lymphoblastoid cells. Exposure of
transfected C3ABR cells to EGF for 16 h led to a significant
down-regulation of luciferase activity in cells transfected with
the ATM promoter construct in agreement with loss of Sp1
binding activity (Fig. 5).
Causal Relationship between Sp1 and ATM Down-regula-
tion—The parallel decrease of ATM and Sp1 binding activity
together with the down-regulation of ATM promoter activity
after EGF treatment suggested that the decrease in Sp1 bind-
ing led to reduced ATM. To test this we employed GM-CSF that
has been shown to increase markedly the DNA binding activity
of Sp1 (34). As observed above, treatment of cells with EGF for
16 h down-regulated the amount of Sp1 binding activity (Fig.
6A, 3rd lane) and subsequent addition of GM-CSF to these cells
caused a rapid (within 1 h) restoration of Sp1 binding activity
(Fig. 6A, 5th lane). Incubation of untreated cells with GM-CSF
also showed evidence of increased Sp1 binding activity (Fig. 6A,
4th lane). EGF caused a down-regulation of ATM protein (Fig.
6B, 2nd lane), and compatible with the increase in Sp1 binding
activity there was also a rapid return of ATM to normal levels
when cells were subsequently treated with GM-CSF (Fig. 6B,
4th lane). Under these conditions Sp1 protein levels did not
change (Fig. 6B). To test whether the reduction in Sp1 binding
activity and ATM down-regulation were responsible for the
EGF-induced radiosensitivity, cells were exposed to radiation
after pretreatment with EGF followed by GM-CSF incubation
for 1 h. A normal pattern of radiosensitivity was observed
compatible with restored levels of ATM protein under these
conditions (Fig. 6C).
Radiation Induces ATM Protein—We investigated whether
radiation might also attenuate the response, since it has been
shown that Sp1 activity is up-regulated by radiation (32, 35),
which in turn should increase the amount of ATM protein.
When C3ABR cells were exposed to radiation (5 Gy) there was
no change in the amount of Sp1 binding activity, but when
these cells were pretreated with EGF initially for 16 h, Sp1
binding activity decreased and subsequent exposure to radia-
tion restored the amount of Sp1 binding activity in 3 h (Fig.
7A). Under these conditions incubation of cells with EGF fol-
lowed by radiation exposure led to an increase in the amount of
ATM protein to untreated levels by 3 h post-irradiation (Fig.
7B). ATM kinase activity increased by 30 min post-irradiation,
and the extent of this increase was somewhat lower in cells
pretreated with EGF (Fig. 7B). By 3 h post-irradiation ATM
kinase induction was the same in cells either untreated or
FIG. 3. Determination of ATM mRNA transcript in lympho-
blastoid cells after incubation with EGF. A, quantitative reverse
transcriptase-PCR was carried out to determine ATM mRNA in C3ABR
lymphoblastoid cells as described previously (31). In these experiments
a DNA fragment (402 bp) corresponding to an A-T mutant (G5319A)
lacking exon 38 was employed as a competitor for ATM cDNA amplifi-
cation from C3ABR cells (nucleotides 5122–5665, 544 bp) in a series of
2-fold dilutions. The amount of competitor DNA added to each sample
was as follows: lane 1, 0.078 attomol/ml; lane 2, 0.156; lane 3, 0.313; lane
4, 0.625; lane 5, 1.25, lane 6, 2.5; lane 7, 5.0; and lane 8, 10 attomol/ml.
Size markers appear on the left-hand side of the figure. Cells were
incubated for 8 and 16 h with EGF (50 ng/ml) as indicated. These
experiments were repeated three times. B, Northern blot analysis of
ATM mRNA form normal human skin fibroblasts (HSF7) after treat-
ment with EGF (50 ng/ml) for various times up to 24 h. Each lane
contained 20 mg of total RNA, and glyceraldehyde-3-phosphate dehy-
drogenase was employed as a loading control. The ATM/glyceraldehyde-
3-phosphate dehydrogenase ratio was determined by densitometry and
represents the relative amounts of ATM mRNA present with time after
EGF treatment.
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pretreated with EGF, at which time ATM protein levels were
the same (Fig. 7B). These data were further supported by
radiation-induced stabilization of p53 and serine 15 phospho-
rylation of p53 with or without prior incubation with EGF (Fig.
7B). The latter provides an in vivo measure of ATM kinase
activation.
DISCUSSION
Activation of ATM kinase by ionizing radiation and other
DNA-damaging agents is critical for modulating its activity in
several DNA damage signaling pathways (36, 37). We have
demonstrated here that ATM can also be altered at the tran-
scriptional level by continuous incubation with EGF over a
16-h period. Under these conditions EGF-treated cells were
more sensitive to subsequent ionizing radiation exposure than
untreated, irradiated cells. Evidence exists for both radiosen-
sitizing and radioprotective effects of EGF, which is dependent
upon both the cell type and position in the cell cycle (25–29,
38–40). In human squamous carcinoma cells, radiosensitiza-
tion by EGF appears to be in part due to increasing the mag-
nitude of radiation-induced G2/M arrest (39). In CaSki cells the
enhancement of radiosensitivity was evident from a reduction
in the shoulder region of the survival curves (27). The degree of
radiosensitization in these cells by EGF was of the same order
as that observed in the present study. None of the previous
studies have provided a mechanistic explanation for radiosen-
sitization, but the down-regulation of ATM in this study pro-
vides a potential explanation. Failure to observe a sensitizing
effect of radiation in A-T cells provides further support for an
Anti-p53 antibody (Oncogene Science) was used as a control. Quantita-
tion of binding activity was determined by densitometry. B, Sp1 levels
were determined by immunoblotting 20 mg of nuclear extract from each
sample in A. Actin was used as a loading control. C, several different
lymphoblastoid cells (C3ABR, C28ABR, C35ABR, and C31ABR) were
treated with EGF for 16 h prior to preparation of extracts for binding to
the Sp1 consensus sequence as described above.
FIG. 4. Effect of EGF on nuclear protein binding to an Sp1-
binding consensus sequence in lymphoblastoid cells. A, nuclear
extracts (20 mg), prepared at different times after EGF addition from
C3ABR, were incubated with 32P-labeled double-stranded oligonucleo-
tide (22-mer) containing a single Sp1-binding site. Free and retarded
fragments were separated on native 5% acrylamide gels. 1st lane is free
fragment only. An Sp1 supershift assay was employed to establish the
specificity of binding. Incubation of nuclear extract and labeled frag-
ment was carried out followed by addition of 1 mg of anti-Sp1 antibody
(Upstate Biotechnology) for 30 min on ice prior to gel electrophoresis.
FIG. 5. Effect of EGF on luciferase activity in cells transfected
with the ATM promoter reporter construct. Common bidirectional
promoter for ATM and NPAT. Luciferase-reporter construct for the
ATM promoter (pGL3ATM). C3ABR were simultaneously transfected
with pGL3-ATM and pRL-CMV (containing the CMV promoter as an
internal control) at a ratio of 2:1. 36 h after transfection the cells were
incubated with 50 ng/ml EGF for 16 h. The activity of the ATM pro-
moter was calculated as ratio of firefly luciferase (pGL3-ATM) to Re-
nilla luciferase (pRL-CMV). The data represent four independent ex-
periments with three samples each. p value was calculated using
Student’s t test.
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association between reduction of ATM and radiosensitivity.
The catalytic component (DNA-PKcs) of a second protein
involved in DNA damage recognition, DNA-dependent protein
kinase (42), was also shown to be down-regulated by EGF, and
this would also be expected to increase the radiosensitivity of
cells. Down-regulation of both ATM and DNA-PKcs suggests
that they may have common regulatory elements responsive to
EGF. Indeed this appears to be the case since both genes are
organized in head-to-head configuration with other genes, and
their putative promoters contain CCAAT boxes and Sp1 con-
sensus sequences. Approximately 0.5 kb separates the 59 end of
the ATM transcript from the 59 end of another NPAT/E14/
CAND3 gene, indicating that they share a bidirectional pro-
moter (21, 22, 34). NPAT plays a role in facilitating the entry of
cells into S phase (43), and ATM activates the p53 pathway to
delay the passage of cells from G1 to S phase after ionizing
radiation exposure (44, 45). DNA-PKcs and Cdc21 (coding for a
protein involved in the initiation of DNA replication (46)) also
share a bidirectional promoter that contains several CCAAT
boxes and Sp1 consensus sites similar to the ATM/NPAT pro-
moter (34, 47). Clearly Sp1 is a candidate for common regula-
tion of these four genes, and its down-regulation or inactivation
might account for the effect of EGF in reducing the amounts of
ATM and DNA-PKcs. Evidence to support this was provided in
a recent report which demonstrated that nitric oxide causes a
4–5-fold increase in expression of DNA-PKcs and protects cells
from the toxic effects of a number of agents including ionizing
radiation (48). The increased expression of DNA-PKcs was
shown to be due to increased binding of Sp1 to the DNA-PKcs
promoter. The mechanism by which nitric oxide enhanced Sp1
binding was not elucidated. We have shown here that a de-
crease in Sp1 DNA binding activity paralleled the EGF-induced
decrease in ATM protein, and when the ATM promoter was
linked to a reporter gene, transcriptional activation was re-
duced by EGF. We have established here that GM-CSF which
enhances the amount of Sp1 DNA-binding activity rapidly re-
verses the EGF-induced down-regulation of ATM. Thus there
appears to be a causal relationship between the reduction in
Sp1 DNA binding activity in EGF-treated cells and the de-
crease in ATM protein. Evidence for a role for EGF in reducing
the amount of Sp1 protein in a rat pituitary cell line (GH4) has
been reported (49). This reduction was accompanied by a 50%
reduction in Sp1 binding to a GC-rich element in the gastrin
promoter, a 50–60% decrease in Sp1-mediated transactivation
of reporter genes and a decrease in cell proliferation. The
results obtained here with several normal human fibroblasts
and lymphoblastoid cells differ from the data with GH4 cells, in
that Sp1 protein remains unchanged as the DNA binding ac-
tivity decreases with time after EGF incubation, and in this
case also there was no decrease in cell proliferation (results not
shown). In our case, it is possible that modification of Sp1
might account for decreased DNA binding activity (35). Several
protein kinases alter the DNA binding activity of Sp1 (50), and
thus alteration in specific sites of phosphorylation of Sp1 could
account for the changes in DNA binding activity reported here.
The human glioblastoma cell line MO59J is characterized by
lack of expression of DNA-PKcs and low levels of ATM protein
and is extremely sensitive to ionizing radiation (47). Thus it
was somewhat surprising in the present study that EGF did
prior to addition of GM-CSF (10 ng/ml) for 2 h. A, Sp1 DNA binding
activity was determined by electrophoretic mobility shift assay. B,
changes in amount of ATM protein detected with anti-ATM antibody.
Sp1 protein levels were measured with Sp1 antibody, and actin was
used as a loading control. C, radiosensitivity was determined as de-
scribed in the legend to Fig. 1. GM-CSF (10 ng/ml) was added to cells for
1 h after 16 h of EGF treatment.
FIG. 6. Restoration of Sp1 DNA binding activity, amount of
ATM, and radiosensitivity GM-CSF after EGF treatment of lym-
phoblastoid cells. Cells were treated with EGF (50 ng/ml) for 16 h
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not increase markedly the radiosensitivity of cells in which
both ATM and DNA-PKcs were down-regulated. This can be
explained by the ability of ionizing radiation to both transcrip-
tionally increase the amount of ATM protein and activate its
kinase activity. Compared with activation of pre-existing ATM
protein which reaches optimal levels by 20 min post-irradiation
(14, 15), EGF-pretreated cells respond more slowly to radiation
showing some kinase activity by 30 min but only reaching
maximum levels by 3 h post-irradiation. This delay in restoring
ATM protein to constitutive levels and in activating ATM ki-
nase appears to account for the reduction in survival in EGF-
pretreated cells, post-irradiation, since up-regulation of ATM
by GM-CSF restored survival to normal levels. Failure of A-T
cells to show any additional radiosensitization also supports
this. Although it is likely that EGF operates via Sp1 in reduc-
ing the amount of ATM protein, it is apparent that radiation
counteracts this. We have shown here that the amount of Sp1
DNA binding activity is rapidly restored when EGF pretreated
cells are exposed to radiation, accounting for the increase in
ATM. Previous results have revealed that Sp1 DNA binding
activity is increased rapidly in human melanoma cells exposed
to ionizing radiation (32, 35).
Clarke et al. (19) were the first to report alterations of ATM
protein in a specific tissue when they failed to detect ATM in
normal breast myoepithelial cells, but a significant level of
expression was present in the proliferative myoepithelium of
sclerosing adenosis. Immunoblotting extracts from freshly iso-
lated PBMCs established that ATM was either absent or pres-
ent at low levels, but increased ;10-fold in response to mito-
genic stimuli over 3–4 days (20). To add to this we have
demonstrated here that ATM protein can be down-regulated by
EGF to radiosensitize cells, but radiation restores ATM to
normal levels and activates its kinase activity, and this is
mediated at least in part by the Sp1 transcription factor that
has several consensus binding sites in the ATM bidirectional
promoter. These observations provide greater insight into the
FIG. 7. Radiation induces Sp1 bind-
ing activity and ATM protein/kinase
in EGF-pretreated cells. A, effect of ra-
diation on Sp1 DNA binding activity.
Cells were either treated with EGF (50
ng/ml, 16 h), radiation (6 Gy, 3 h) alone, or
with EGF for 16 h followed by radiation (6
Gy) and subsequent incubation for 3 h.
Binding to an Sp1 consensus sequence
was as described in the legend to Fig. 4. B,
effect of radiation on ATM protein and
ATM kinase. Untreated or EGF (50 ng/
ml, 16 h)-treated cells were subsequently
exposed to radiation (6 Gy) and incubated
for either 30 min or 3 h prior to prepara-
tion of extracts. ATM kinase activity was
determined using p531–40 as a substrate
(14), and ATM protein was also deter-
mined in immunoprecipitates. p53 pro-
tein and serine 15 phosphorylated p53
were determined in parallel samples by
immunoblotting with specific antibodies.
Actin was used as a loading control.
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regulation of ATM that involves not only activation of pre-
existing protein but also alterations in the amount of ATM
protein in response to different stimuli. Determination of ATM
expression levels in different tissues/cell types may provide
further insight into the response of different tissues to radia-
tion and the factors involved in transcriptional control of the
ATM/NPAT promoter. Finally, the results described here raise
a fundamental issue in relation to radiosensitization by atten-
uating ATM protein. Reduction of ATM, in this case by EGF, is
countered by radiation exposure that rapidly restores ATM to
constitutive levels and would be expected to lessen any thera-
peutic benefit of radiation. A combination of attenuating ATM,
together with inhibitors of its activity, may be a more effective
solution.
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